Abner Antonio Murray, Hematology/Oncology Fellow at UNC School of Medicine, shared on X:

“New data from the phase 3 HERTHENA-Lung02 trial at ASCO 2025: Patritumab deruxtecan (HER3-DXd) shows PFS benefit over platinum-based chemo in EGFR-mutant NSCLC post–3rd generation EGFR TKI.

PFS: HER3-DXd reduced risk of progression/death vs PBC (HR 0.77, p=0.011)

Intracranial activity: ORR 19%, mPFS 5.4 mo vs 4.2 mo (PBC)

Biomarker work ongoing to assess predictive role of HER3 IHC

Safety: Manageable, mainly hematologic and GI. ILD adjudicated in 5.2% (Grade 5 in 0.7%)

Early ILD onset (median ~4 wks), prompting close monitoring

OS: No improvement over chemo in 3rd interim analysis (HR 0.98)

Clinical takeaway: HER3-DXd offers a chemo-sparing option with intracranial activity and modest PFS gains, but without a confirmed OS benefit Will not be available to patients.”

Abner Antonio Murray: New data from the phase 3 HERTHENA-Lung02 trial at ASCO 2025

“New data from the phase 3 HERTHENA-Lung02 trial at ASCO 2025: Patritumab deruxtecan (HER3-DXd) shows PFS benefit over platinum-based chemo in EGFR-mutant NSCLC post–3rd generation EGFR TKI.

PFS: HER3-DXd reduced risk of progression/death vs PBC (HR 0.77, p=0.011)

Intracranial activity: ORR 19%, mPFS 5.4 mo vs 4.2 mo (PBC)

Biomarker work ongoing to assess predictive role of HER3 IHC

Safety: Manageable, mainly hematologic and GI. ILD adjudicated in 5.2% (Grade 5 in 0.7%)

Early ILD onset (median ~4 wks), prompting close monitoring

OS: No improvement over chemo in 3rd interim analysis (HR 0.98)

Clinical takeaway: HER3-DXd offers a chemo-sparing option with intracranial activity and modest PFS gains, but without a confirmed OS benefit Will not be available to patients.”